# Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

> **NCT06517511** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 42 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Selinexor Oral Tablet [Xpovio]
- **DRUG:** R-CHOP Protocol

## Key facts

- **NCT ID:** NCT06517511
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2027-01
- **Final completion:** 2028-04
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06517511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06517511, "Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06517511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*